<DOC>
	<DOCNO>NCT01401452</DOCNO>
	<brief_summary>The aim post-marketing observational study ( PMOS ) assessment effectiveness Adalimumab moderate severe Plaque Psoriasis patient distinct co-morbidities impact Adalimumab quality life routine clinical praxis period 9 month . Psoriasis associate several co-morbidities depression , obesity metabolic syndrome . Until unclear co-morbidities due pathophysiology psoriasis psoriasis-associated behavior ( e.g . smoke alcohol abuse ) . Disease severity correlate smoke alcohol abuse . The severity psoriasis shall establish treatment Adalimumab calculation Psoriasis Area Severity Index ( PASI ) analysis Dermatology Life Quality Index ( DLQI ) Patients last one co-morbid disease and/or symptom . Also prevalence co-morbidities consideration gender parameter Life Quality ( SF-36 ) Life-Quality specific co-morbidities evaluate .</brief_summary>
	<brief_title>Effectiveness Adalimumab Moderate Severe Plaque Psoriasis Patients With Distinct Co-morbidities</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients Adalimumab therapy indicate prescribed accord product label meet follow criterion : Patients age &gt; = 18 year Moderate severe Plaque Psoriasis patient last one comorbid disease and/or symptom hypertension , Psoriasis Arthritis confirm rheumatologist , obesity , diabetes , metabolic syndrome depression . Adalimumab naïve patient moderate severe Plaque Psoriasis unsatisfactory response non tolerability contraindication systemic therapy ciclosporin , methotrexate PUVA ( psoralen + UVA ) biological disease modify antirheumatic drug ( BDMARDs ) failure ( e.g . : infliximab , etanercept ustekinumab ) Patients must fulfill Austrian Treatment Recommendations use BDMARD Psoriasis ( Chest Xray IGRA* interferon gamma release assay PPDskin test negative tuberculosis ) Patient willing consent data anonymous collect provided Abbott . Patient must able willing selfadminister Adalimumab injection qualify person available administer Humira® syringe Humira® Pen injection . The following patient include observational study : Patients meet contraindication outline late version Humira syringe® Summary Product Characteristics ( SPC ) Humira Pen® SPC . Patients participate another study program clinical trial . Patients treat Humira® .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Monoclonals</keyword>
	<keyword>Moderate severe plaque psoriasis</keyword>
	<keyword>Psoriasis Area &amp; Severity Index ( PASI )</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Biological disease modify anti-rheumatic drug ( BDMARD )</keyword>
	<keyword>Co-morbidities</keyword>
	<keyword>Antibodies</keyword>
	<keyword>Disease Life Quality Index ( DLQI )</keyword>
</DOC>